Skip to main content

Table 2 UVA of number of metastases with clinical outcome

From: Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

 

OS

PFS

CB

Number of Metastases

HR (CI)

p-value

HR (CI)

p-value

OR (CI)

p-value

1 (n = 24)

0.47 (0.22–1.01)

0.054

0.60 (0.35–1.05)

0.072

4.37 (1.40–13.64)

0.011*

2 (n = 33)

0.39 (0.20–0.78)

0.007*

0.45 (0.27–0.77)

0.003*

4.24 (1.48–12.17)

0.007*

3+ (n = 33)

–

–

–

–

–

–

  1. UVA Univariate analysis, OS overall survival, PFS progression-free survival, CB clinical benefit, HR Hazard Ratio, CI Confidence Interval, OR Odds Ratio
  2. *statistical significance at alpha < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us